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article under the CC BY-NC-ND license (Abstract Background/purpose: Oral submucous fibrosis (OSF) is a potentially malignant dis-
order of oral squamous cell carcinoma (SCC). In this study, we obtained the genetic expression
signatures of OSF and SCC by microarray analysis.
Materials and methods: Five patients with clinically evident OSF, five patients with SCCwho also
had existing OSF, and four normal volunteers who did not have a history of chewing betel quids
were recruited. Biopsy specimenswere obtainedwith an approved Institutional ReviewBoardpro-
tocol. Total RNA fromOSF or SCCwas isolated and hybridized to a Human Oligo 1A (V2) Microarray
(G4110B) chip against normal control RNA that was pooled from the four healthy volunteers.
Results: We found similar, but distinct genetic expression signatures for OSF and SCC. At the hier-
archical clustering analysis, 24 known genes (23 upregulated and 1 downregulated) in OSF were
differentially expressed consistently in all participants. Among the genes, XRCC5 was cloned
and transfected into oral cancer GNM cells. The results demonstrated that the overexpression
of XRCC5 increased the resistance of GNM cells to low-density X-ray irradiation and promoted
the cell growth rate.
Conclusion: The distinct but similar genetic expression signatures seen in OSF and SCC suggested
that this expressionmay be used as a supplemental diagnostic tool in pathology practice. This pre-
liminary study showed that theXRCC5 genepromotedGNMcell growth and conferred resistance to
low-density X-ray irradiation. Further studies on the effect of XRCC5 in oral cancer cells are in
progress.
Copyright ª 2013, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).of Dentistry, College of Oral Medicine, Chung Shan Medical University, 110, Section 1, Chien-Kuo N.
.tw (Y.-F. Huang).
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458 P.-H. Liao et alIntroduction Review Board of the Chung Shan Medical University Hospi-Oral submucous fibrosis (OSF) is a progressively scarring
chronic disease of the oral mucosa. It is characterized by
increasing mucosal rigidity that is caused by the prolifera-
tion of fibroelastic tissue and the deposition of dense
fibrous connective tissue in the superficial submucosa
resulting from increased collagen synthesis,1,2 decreased
collagenase activity,3 or both. Oral submucous fibrosis is
frequently associated with the habitual chewing of betel
quid, which is a prevalent habit in Southeast Asia.4 The
disease affects 0.2e1.2% of the urban population that visits
dental clinics in India.5 A recent study on OSF showed that,
of the 2 million people in Taiwan who habitually chew betel
quid, 85.4% will develop OSF6 and one-third of these pa-
tients may eventually develop squamous cell carcinoma
(SCC). Therefore, OSF is a potentially malignant disorder of
the oral mucosa that may develop into oral squamous cell
carcinoma (SCC).1
Despite its potential for malignant transformation, it is
difficult to predict on the basis clinical and histopathologic
examinations alone whether OSF will develop into a ma-
lignancy. Previous studies of OSF on the molecular mecha-
nism of premalignant transformation of the oral mucosa
have identified some molecules such as COX-2,7 type I
plasminogen activator inhibitor,8 p53,9,10 keratinocyte
growth factor-1,11 interleukin-6,12 tissue inhibitor of
metalloprotease 1,13 and adenomatous polyposis coli.10
However, these studies were insufficient in discriminating
OSF from SCC.
This study used a microarray analysis to identify poten-
tial biomarkers that can predict the malignant trans-
formation of OSF. The results support the hypothesis that
every cancerous or precancerous lesion may possess a
specific genetic expression signature that can be distin-
guished from others after hierarchical clustering analysis.Materials and methods
Case recruitment
Oral mucosal specimens were collected, as described by
other researchers, from five patients with clinically evident
OSF.14,15 Clinical signs and symptoms include trismus,
marble-like pallor on the buccal mucosa and a progressive
stiffness of subepithelial tissue, and a grayish white oral
mucosa.1 All patients came to the Oral Surgery Clinic at the
Chung Shan Medical University Hospital (Taichung City,
Taiwan) for diagnosis and treatment. A review of their so-
cial habits showed all patients were smokers and areca nut
chewers. Specimens of SCC were also collected from five
patients who were undergoing surgical removal of the tu-
mors at the same hospital. All five patients had SCC in the
presence of clinically evident OSF and were all smokers and
areca nut chewers. Normal tissues were obtained from the
posterior mucobuccal fold of four healthy volunteers who
did not have any history of chewing betel quid and were
undergoing mandibular third molar extraction. All patients
and volunteers were male and between the age of 30 and 55
years. The study protocol was approved by the Institutionaltal. All patients with OSF or SCC and the healthy volunteers
were provided with research information and informed
consent was obtained from everyone before the study. All
specimens were immediately frozen in e80C until further
use. The RNA extracted from the four healthy volunteers
was pooled as one normal control for all microarray hy-
bridization test, which is described later.
RNA extraction
The RNA extraction, labeling, and microarray analysis were
performed in cooperation with DigiGenomics Co., Ltd.
(Taipei county, Taiwan). In brief, the collected tissue
samples were pulverized into fine powder in liquid
nitrogen-filled mortar. They were then homogenized in TRI
REAGENT (Molecular Research Center, Inc., Cincinnati, OH,
USA). The total RNA was extracted in accordance with the
manufacturer’s protocol. To remove residual genomic DNA,
50 mg or less of total RNA was treated with Ambion RNase-
free DNase I (Ambion, Austin, TX, USA) in accordance with
the manufacturer’s protocol. The enzyme was then
removed by phenol/chloroform extraction. The RNA was
recovered by ethanol precipitation. The integrity of RNA
was checked in 0.9% agarose run in tris-acetate-EDTA (TAE)
buffer to ensure that the RNA was of good quality for sub-
sequent labeling steps.
Labeling and hybridization
The total RNA (1 mg) from each tissue sample was reverse
transcribed into cDNA, further transcribed in vitro into
cRNA, and labeled with CyDye by using the MessageAmp
aRNA kit (Ambion, Austin, TX, USA) in accordance with the
manufacturer’s protocol. The cRNA obtained from the RNA
sample of the normal tissue was labeled with Cy3 and was
the reference sample. The cRNA obtained from the RNA
sample of the diseased tissue was labeled with Cy5 and was
the experimental sample. The labeled cRNA of the refer-
ence and experimental sample was purified to remove
uncoupled CyDyes, combined in equal amounts, and mixed
with 2 hybridization buffer (based on the manufacturer’s
protocol) before hybridization onto Human Oligo 1A (V2)
Microarray (G4110B) (Agilent Technologies, Inc., Santa
Clara, CA, USA). The array contains approximately 22,000
oligonucleotides, representing more than 20,000 genes.
Conditions and procedures for hybridization and washing
followed the Agilent 60-mer oligo microarray processing
protocol (Agilent Technologies, Inc., Santa Clara, CA, USA).
Microarray image analysis, data normalization, and
data analysis
Microarray images were acquired by using the GenePix
4000B scanner (Axon Instruments, Union City, CA, USA). The
image was analyzed by using GenePix Pro 5.1 software
(Molecular Devices Corporation, Downingtown, PA, USA).
Individual microarray data was normalized by using
Expressionist Pro Refiner software (Genedata AG, Basel,
Switzerland). A filter procedure was applied to eliminate
nongene features such as positive controls, negative
Figure 1 Genetic expression signatures of OSF and SCC.
Groups I, II, III and IV represented gene clusters that can most
discriminate OSF from SCC, among which, 24 known potential
genomic biomarkers were selected.
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before data processing. Background correction was applied
to genes with an S/N ratio over 2. Nonlinear normalization
(i.e., Lowess) was performed globally with the smoothness
factor set at 0.3.
Expression profiling was analyzed by using Expressionist
Pro Analyst software (Genedata AG, Basel, Switzerland). All
microarrays were normalized before comparison by using
median intensity set at a fixed value and with the reference
value set at 1. Features were excluded from analysis when
the S/N ratio was less than 2.0.
To find common upregulated and downregulated genes
among the samples, a threshold of expression ratio greater
than 1.5 or less than 0.67 is the set criterion for screening
significant genes. Genes passing this criterion in more than
50% of microarray experiments are chosen for subsequent
hierarchical clustering.
Hierarchical clustering analysis
The hierarchical clustering analysis was performed, based
on complete linkage and Manhattan (L1) distance. Clusters
of genes showing opposite expression profiles between two
distinct stages were chosen.
Cloning the full length XRCC5 cDNA
Total RNA from normal oral tissue was isolated from healthy
volunteers. Reverse transcriptase polymerase chain reac-
tion (RT-PCR) was performed with a primer pair that can
amplify the full length of XRCC5 cDNA. The size of RT-PCR
product was verified with electrophoresis (w2.2 kb).
The same RT-PCR reaction was performed with the same
primer pair and the resultant reaction solution was ligated
to a pcDNA3.1 vector by using the TOPO TA cloning kit (Life
Technologies, Grand Island, NY, USA). The reaction was
transformed to TOP10’ competent cells. After culturing on
agarose plate, positive colonies were selected and the
plasmid DNA was prepared by using the QIAprep Spin Mini-
prep kit (Qiagen, Germantown, MD, USA). The XRCC5 cDNA
sequence was verified by a sequencing procedure.
Cell culture
GNM cells were originally derived from a 63-year-old female
patient who was diagnosed as having gingival SCC with neck
lymph node metastasis.16 Transfected GNM cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum and 1%
antibiotics.
Transient transfection
Oral cancer GNM cells were plated at 1  106 cell density
per well in six-well dishes. Two milliters of DMEM with 10%
FBS was added to the wells and lipofectamine 2000/DNA
mixture was added into each well in accordance with the
manufacturer’s instructions. In brief, 4 mg plasmid DNA
(XRCC5 or pcDNA) was diluted in 250 mL DMEM, mixed
with 10 mL Lipofectamine 2000, and diluted in 250 mL
DMEM at room temperature for 2e5 minutes to form aDNA-Lipofectamine 2000 complex. Culture media were
removed and cells were washed with PBS twice, followed
by 1500 mL 10% FBS DMEM. The DNA-Lipofectamine2000
complex was then gradually inserted into the wells. The
dishes were gently rocked and incubated in 5% CO2-
containing chamber for 24 hours. Cells were collected 24
hours, 48 hours, and 72 hours after transfection.
Results
With a cut-off threshold of 1.5-fold (upregulated) or 0.67-
fold (downregulated) in at least 50% of the comparisons, we
found 1015 differentially expressed genes (approximately
5% of the total genes). The hierarchical analysis provided
genetic expression signatures of OSF and SCC, which were
distinct, but very similar. (Fig. 1) The hierarchical clus-
tering analysis identified four clusters (Group I to IV in
Fig. 1) that could discriminate OSF from SCC. Among these,
24 known genes (23 upregulated and 1 downregulated) in
OSF were consistently expressed in all five cases of OSF in
comparison to all cases of SCC. This therefore provided the
most discriminating power (Table 1). Among the 24 differ-
entially expressed genes, downregulation of XRCC5 in SCC
in comparison to OSF was confirmed by quantitative RT-PCR
and was cloned for further studies.
To study if the cell growth was influenced by the over-
expression of XRCC5, GNM cells were transiently trans-
fected with pcDNA3.1 or with XRCC5. The cells were
harvested at 24 hours, 48 hours, and 72 hours after trans-
fection. The cell growth rate was calculated as the ratio of
the cell number difference to the cell count at the earlier
time point. The results showed that the growth rate of
XRCC5-transfected GNM cells was higher than the growth
Table 1 Genomic biomarkers identified in cDNA microarray that may predict malignant transformation of OSF.
Assession # Gene ID Fold change
AF098269 Procollagen C-endopeptidase enhancer 2 2.1 e up
AF329483 Testis-specific serine kinase 6 2.4 e down
AK001592 b-carotene 15,15’-monooxygenase 1 2.3 e up
AK024892 SH3 domain binding glutamic acid-rich protein like 1.6 e up
AK026775 Regulator of G-protein signaling 5 3.4 e up
AK098393 Glycine amidinotransferase 3.1 e up
AL833232 Hemicentin 2.6 e up
BC002580 Zine finger protein 593 3.0 e up
BC014418 Superoxide dismutase 3 1.5 e up
BCO17396 Prostatic binding protein 1.9 e up
BC022279 Leukocyte immunoglobulin-like receptor 1.7 e up
BC033721 SPARC-like 1 4.4 e up
BC035782 Tyrosine kinase, non-receptor 1 3.7 e up
D12485 Ectonucleotide pyrophosphatase/phosphodiesterase 1 3.4 e up
D67031 Adducin 3 2.6 e up
M30938 XRCC5 2.2 e up
NM000385 Aquaporin 1 3.9 e up
NM002404 Microfibrillar-associated protein 4 3.9 e up
NM019113 Fibroblast growth factor 21 2.6 e up
NM032280 Zine finger, CCHC domain containing 9 3.1 e up
NM133267 Homeobox protein GSH-2 1.5 e up
NM152407 GrpE-like 2, mitochondrial 1.7 e up
U02570 Rho GTPase activating protein 1 2.8 e up
Z70293 Chemokine ligand 14 2.5 eup
OSF Z oral submucous fibrosis.
460 P.-H. Liao et alrate of the control group (Fig. 2). When the transfected
cells were irradiated with 70 kvp at 10 mA (Minray intraoral
X-ray unit, Soredex, Shenzhen, China) at a distance of 2 cm
for 3 seconds (approximately 0.015 mSv), the growth rate
was calculated as the ratio of the X-ray irradiated group to
the nonirradiated control group. The results showed that
fewer XRCC5-transfected cells died from X-ray irradiation
and they grew faster at 24 hours and 48 hours after irra-
diation (Fig. 3).Figure 2 The proliferation of XRCC5 transfected GNM cells
with X-ray irradiation. Data are presented as ratios of X-ray
irradiated to non-irradiated groups.Discussion
We have reported the genetic expression signature from
the epithelium of OSF by using laser capture microdissec-
tion and a cDNA microarray analysis.17 To demonstrate the
usefulness of the genetic expression signature in dis-
tinguishing diseases, five cases each of OSF and SCC were
included in the microarray analysis. The genetic expressionFigure 3 The growth rate observed between 24e48h and
48e72h with X-ray irradiation.
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as were the genetic expression signatures in the SCC group
(Fig. 1). It is also very interesting that these two diseases
showed different genetic expression signatures, but with
certain degrees of similarity. This is different from the
cases of synovial sarcoma and fibrosarcoma which show
completely different genetic expression signatures were
demonstrated between OSF and SCC.18 An interpretation of
this finding is that OSF is a potentially malignant disorder of
SCC, but synovial sarcoma and fibrosarcoma are totally
unrelated diseases. Therefore, we hypothesized that every
disease or tumor possesses a unique genetic expression
signature that, in the future, may be used as a molecular
diagnostic tool. However, to do so, it is important to realize
that one single normal tissue group should be used as
control for all hybridizations, and more disease entities
should be included for examination.
With the rapid progression in molecular biology research,
modern technology such as the Affymetrix array (Santa
Clara, CA, USA) may survey thousands of genes at one time
to identify potential biomarkers. However, our cDNA
microarray has identified 24 known genes that were
consistently and differentially expressed in all five OSF
cases, compared to the five cases of SCC. Limited cases
were included in this study, although a similar approach has
been applied in different expression array-based studies
with a limited case number.19e22
It would be ideal to use normal tissue from the same
patient for microarray analysis, as reported by Shieh
et al.13,23 In another study on oral SCC, cDNA microarray
analysis used normal tissue from the same patient as the
control for the analysis.24 However, it is impractical to
obtain clinically and biologically normal tissue from pa-
tients with OSF or SCC. As other scientists have shown,
peritumor normal tissue may not be totally normal in that
cancer cells nay influence the gene expression of the
adjacent tissue.24 To eliminate the possible contamination
of the tissue samples, we decided to use normal tissues
from healthy volunteers who did not have any history of
chewing betel quids. We pooled their RNAs as one normal
control for microarray analysis to minimize possible
variations.
X-ray cross-complementing (XRCC) genes were discov-
ered mainly through their role in protecting mammalian
cells from damage caused by ionizing radiation. They are
also important in genetic stability. There are two main
pathways in eukaryotic cells for repairing double strand
DNA breakagednamely, nonhomologous end joining and
homologous recombination (HR). Nonhomologous end
joining provides a mechanism for the repair of double
strand DNA breakage throughout the cell cycle. However, it
is particularly important during the G0, G1, and early S
phases in mitotic cells and is mediated by the XRCC5,
XRCC6 and XRCC7 genes. The DNA repair protein Ku acts as
a heterodimer of the two 70-kDa (Ku70) and 80-kDa (Ku80)
subunits and binds to DNA ends, nicks, or single- to double-
strand transition.25e27 It serves as a DNA-binding compo-
nent of the DNA-dependent protein kinase (DNA-PK) that
phosphorylates certain chromatin-bound proteins in vitro.
The XRCC5 gene encodes Ku80 and forms a heterodimer
with Ku70 and functions as DNA end-binding at the double
strand breakage site. Ku binds to the end of the DNAdouble-strand breakage and appears to stabilize the bind-
ing of the DNA-PKCs to DNA.28e35
No data have reported the association of XRCC5 gene in
OSF and/or in the subsequent development of SCC. How-
ever, a recent study has demonstrated frequent chromo-
somal breakage at the 1cen-1q12 region in the mucosa cells
of betel nuts chewers.36 It has also been shown that the
suppression of Ku70 increases radiosensitivity in one human
lung carcinoma cell line.37 It is thus possible that the
upregulation of the XRCC5 gene in the OSF patients in our
study reflects a repair mechanism of DNA breakage,
whereas the decreased expression of the XRCC5 gene in SCC
possibly signifies an increased potential for malignant
transformation of OSF to SCC.
The effects of X-ray irradiation on GNM cells transfected
with the XRCC5 gene were preliminarily studied. However,
only dental periapical irradiation was tested in this pre-
liminary study, which emits relative low radiation. The
XRCC5-transfected GNM cells were interestingly more
resistant to low-dose X-ray irradiation and had enhanced
cell growth. Higher doses of irradiation should be tested to
understand more about the effects of XRCC5 on the cells.
In summary, hierarchical clustering analysis showed
distinct, but similar genetic expression signatures of OSF
and SCC. The genetic expression signature in OSF and SCC
and other cancers17,18 renders this analysis a possible
diagnostic tool in the future. Preliminary studies also
showed that XRCC5 gene overexpression enhanced GNM cell
proliferation and provided more resistance to low-dose
X-ray irradiation. Further studies on the effects of XRCC5
will be performed in the future.
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